Ascendis Pharma A/S
TransCon CNP and TransCon hGH
achondroplasia
Resolved
98days ago
Phase 3 readout · ~ Mar 31, 2026 estimated
What's at stake
Phase 3 trial results for TransCon CNP and TransCon hGH in achondroplasia are due ~ Mar 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“In Q4 2025, Ascendis submitted a protocol and held an end of Phase 2 meeting with the FDA regarding a Phase 3 trial of TransCon CNP and TransCon hGH in pediatric achondroplasia.”